

1 **Protocol for a randomized cross-over study measuring the effect of reduced protein**
2 **intake on autophagic flux in healthy adults.**

3 Célia Fourrier ^{1,2}, Leonie K. Heilbronn ^{2,3}, Xiao Tong Teong ^{1,2}, Jemima R. Gore ⁴, Timothy J.
4 Sargeant ^{1,2} *, Julien Bensalem ^{1,2}

5

6 1 Lysosomal Health in Ageing, Hopwood Centre for Neurobiology, Lifelong Health Theme,
7 South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

8 2 Faculty of Health and Medical Sciences, The University of Adelaide, South Australia,
9 Australia.

10 3 Obesity and Metabolism, Nutrition, Diabetes & Gut Health, Lifelong Health Theme, South
11 Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

12 4 SAHMRI Clinical Trials Platform, South Australian Health and Medical Research Institute,
13 Adelaide, South Australia, Australia.

14

15 * *Corresponding author:*

16 Timothy J. Sargeant (tim.sargeant@sahmri.com)

17

18

19

20

21

22

23

24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract**

27 Autophagy is a cellular mechanism that degrades damaged or unwanted material from cells
28 and is particularly important during ageing. Autophagy has been widely studied in pre-clinical
29 models and is known to respond to nutrient availability and in particular amino acids. However,
30 clinical data are limited. This protocol paper describes a randomized cross-over clinical study
31 investigating the effect of a four-week long reduction of dietary protein intake on autophagic
32 flux (autophagic degradative activity) measured via a blood test in healthy adults. Sixty-one
33 healthy participants will be recruited. Study participants will be randomly assigned to one of
34 two diets for four weeks, then cross over to the other diet with a four-week washout period
35 between diets. The diets will be: 1) Average Protein Diet: a control comparator diet with a
36 macronutrient profile of 20% of energy from protein, 35% from fat (<10% saturated) and 45%
37 from carbohydrate, with >30 g of fiber/day; 2) Reduced Protein Diet: 10% protein, 35% fat
38 (<10% saturated), 55% carbohydrate, >30 g of fiber/day. This diet will provide 0.7 g of protein
39 per kg of body weight (the recommended minimum daily protein intake). The primary outcome
40 will be the change in autophagic flux between each diet. This study aims to determine whether
41 reducing dietary protein intake in healthy adults can increase autophagy in humans. If positive,
42 it creates the possibility that nutritional strategies could be used to prevent or delay autophagy-
43 related diseases such as Alzheimer disease or atherosclerosis.

44

45 **Trial registration**

46 Australian New Zealand Clinical Trials Registry (ANZCTR), anzctr.org.au
47 ACTRN12623000260628. Registered on 10 March 2023.

48

49 **Keywords**

50 Autophagy; Protein; Amino acids; Nutrition; mTORC1; LC3.

51

52 **Background**

53 Autophagy is an intracellular process that collects and degrades unwanted or damaged
54 organelles and macromolecules and recycles the degraded material to replenish macronutrients
55 during nutritional stress. Autophagy is critical for healthy cellular function and the prevention
56 of age-related disease (1). Autophagy therefore represents an important target for treatments
57 that seek to prevent or delay age-related disease. Amongst potential mediators of autophagy,
58 nutrient restriction has been shown to induce autophagy in *in vitro* and *in vivo* studies (2, 3),
59 notably through inhibition of the mechanistic target of rapamycin complex 1 (mTORC1) (4).
60 Reduced protein intake was shown to reduce mTORC1 activity (5, 6) and increased
61 carbohydrate:protein ratios were associated with increased lifespan in animals (7), and is
62 correlated with reduced risk of death in people aged 50-65 and reduced risk of cancer and
63 diabetes mortality over an 18-year follow up (8). Protein consumption in humans increased
64 mTORC1 activity in monocytes and changed LC3-positive puncta abundance, consistent with
65 a decrease in autophagy, although autophagic *flux* itself was not assessed in that study (9).
66 Consistent with these data, it has been shown that high protein diets increase mTORC1 activity
67 and decrease lysosomal system function to exacerbate a model of heart disease (9, 10).

68 It is important to note that measuring autophagic degradation activity, named autophagic
69 flux, is particularly challenging in humans. Indeed, existing methods require either genetic
70 manipulation (e.g. a transgene coding for a fluorescent probe) (2, 11, 12) or the use of a
71 lysosomal inhibitor such as chloroquine or bafilomycin to block degradation of autophagic
72 material by the lysosome (12, 13). Amounts of LC3-II, a marker of autophagic vesicles, can be
73 measured to determine how much autophagic material should have been degraded during the
74 lysosomal inhibition period in comparison to a non-treated paired sample. To study autophagic
75 flux in humans, we have developed a method where the lysosomal inhibitor chloroquine is

76 added to whole blood from fasting participants, and autophagic flux is measured in peripheral
77 blood mononuclear cells (PBMCs) isolated from these treated blood samples (14). LC3-II
78 quantification is performed by enzyme-linked immunosorbent assay (ELISA). This method
79 measures autophagic flux from cells in a physiological environment (participant's blood) in
80 comparison to cells that would be cultured in a nutrient-rich artificial culture medium which
81 could itself alter autophagy (2, 15, 16).

82 The aim of this randomized cross over trial is to establish whether a four-week-long
83 reduction of dietary protein intake increases autophagic flux in healthy adults as compared to
84 a moderate protein intake, approximating habitual diets in Australia (17).

85

86 **Methods and design**

87 *Ethics and study registration*

88 The Human Research Ethics Committee (HREC) of the University of Adelaide on 31st
89 August 2021 (HREC reference number: H-2021-154, current version at submission of this
90 paper: v5.2 dated 30th May 2024) gave ethical approval for this work. Serious adverse events
91 considered to be related to the study will be reported to the HREC by the PI.

92 The study was registered on anzctr.org.au with the following identifier:
93 ACTRN12623000260628 and entitled '*Effect of Nutritional INterventions on Autophagy: The*
94 *NINA study*'. The NINA study is a single-site study performed at the South Australian Health
95 and Medical Research Institute (SAHMRI) in Adelaide, South Australia, Australia, by
96 researchers from SAHMRI and the University of Adelaide.

97 *Study design*

98 The NINA study is a single-site, single-blinded, randomized cross-over study.

99 *Intervention masking*

100 Given that the NINA study is a diet intervention study, the investigator interviewing the
101 participants and providing the diets will not be blinded to the group assignments. However, the
102 laboratory work, data management and final analyses of the primary outcomes will be carried
103 out by technical investigators who are blinded to each participant's allocated group.
104 Participants will be blinded to dietary interventions. To prevent study participants from trying
105 to guess which diet is the 'Average Protein Diet' and which diet is the 'Reduced Protein Diet'
106 and therefore avoid bias, the participant information sheet does not outline the purpose of the
107 study which is to investigate the effect of dietary protein intake on autophagy (**Additional file**
108 **1**). The wording has been kept general and states that the study aims to measure the effect of
109 diet composition on autophagy in humans. The macronutrient profile of the diets will be
110 manipulated with the assistance of a high or low protein supplemental powder to keep the diets
111 as similar as possible and to mask the identity of the diets as much as possible.

112 *Participants*

113 Participants are recruited from the Adelaide metropolitan area (South Australia, Australia).
114 The study is advertised through SAHMRI and The University of Adelaide networks and on
115 social media.

116 Participant inclusion and exclusion criteria for the study are listed in **Table 1**.

117 **Table 1. Participant inclusion and exclusion criteria**

Inclusion criteria
<ul style="list-style-type: none">• Aged between 20 and 50 years of age• BMI between 18.5 and 29.9 kg/m²
Exclusion criteria
<ul style="list-style-type: none">• Diagnosis or evidence of neurodegenerative disorder such as Alzheimer disease.• Any co-morbidities that are likely to change the activity of the lysosomal system, such as cancer, diabetes, cardiovascular disease/conditions (stroke, heart attack, high blood pressure), renal or liver disease, hemoglobin disorder or anaemia, gastrointestinal surgery or disease, major psychiatric disorders (schizophrenia, addiction, eating disorders, unstable major depressive disorder), neurological disorders, and/or any other condition deemed likely to affect the results by the study principal investigator.• Taking any medications that, in the opinion of the investigator, might change autophagic activity; including, but not restricted to, chronic medications or supplements that change appetite, body composition or metabolism (e.g. medications used to lower blood glucose, antidiabetic medications), anti-

inflammatory medications, medications used in the treatment of cancer or cardiovascular disorders. Female participants taking hormonal contraceptive will not be excluded from the study. It is preferable but not essential that women attend the V1 baseline study appointment between day 1 and day 10 of their menstrual cycle. Date of first day of menstrual cycle will be documented as well as cycle length in days at both Screening Visit and Metabolic Visits.

- Anyone who is not weight stable (lost or gained > 5% body weight in the last 3 months)
 - Current alcohol abuse (>14 standard drinks/week) and/or substance use disorder
 - Current smoker
 - Vegan
 - Lactose intolerance
 - Pregnant or breastfeeding women or women planning a pregnancy
 - Women who have been through menopause or peri-menopausal
 - Self-reported dietary practice or restriction that may affect autophagy (including calorie restriction, intermittent fasting and ketogenic diets).
 - Self-report of high consumption of protein or supplements
 - Anyone who has an eating disorder, food allergies or practices that are likely to interfere with compliance (eg. coeliac, gluten intolerance and nut allergies)
 - Anyone who is unable to comprehend the study protocol (i.e. due to English language or cognitive difficulties)
 - Anyone with a pacemaker or other internal electronic medical devices.
-

118

119 *Screening*

120 Interested participants are invited to complete an online screening questionnaire using
121 REDCap (Research Electronic Data Capture) which gathers demographic and health-related
122 information, including diet, medical, and exercise history, to assess their eligibility for the study
123 (**Table 1**). At this time, volunteers will also be asked to complete the Night Eating Diagnostic
124 Questionnaire (NEDQ) (18) via REDCap to assess the presence of night eating syndrome
125 which would exclude them from the study. Participants are also provided with a copy of the
126 participant information sheet (**Additional file 1**) and allowed as much time as they require to
127 decide whether they would like to participate.

128 Potentially eligible participants will be invited to attend SAHMRI and have the research
129 protocol explained to them in detail. Informed consent to participate in the study, including a
130 verbal indication that they understand the general study protocol and requirements will then be
131 obtained (**Additional file 1**). During this session, weight and height will be obtained using
132 standardized procedures to calculate body mass index and ensure suitability for inclusion into

133 the trial. Participants will be asked for the duration of the study not to change their exercise.
134 Baseline exercise level will be measured at screening using the International Physical Activity
135 Validated Questionnaire (IPAQ). Participants will also be asked to complete a 3-day habitual
136 food diary prior to starting the study diet to get an indication of their usual eating habits for use
137 in the analysis. If participants meet the eligibility criteria, they are invited to continue in the
138 remainder of the study. Participants are free to withdraw from the project at any time.

139

140 *Randomization*

141 Randomization of participants will be stratified by sex into one of the two study diets at
142 baseline with a ratio of 1:1. The allocation sequence will be determined by a computer-
143 generated random number sequence, using a permuted block design. The randomization
144 schedule will be built into REDCap and unable to be manipulated by research staff.

145

146 *Study intervention*

147 Study diets are designed by a research dietitian using FoodWorks Professional (version 10;
148 Xyris Software (Australia) Pty Ltd., Australia). To aid compliance, participants will be
149 provided with individualized 7-day rotating menus to accommodate personal preferences (e.g.
150 cultural preferences, food intolerance, vegetarian) with most of the food provided. Participants
151 will also be asked to complete food checklists daily, recording any food prescribed that was
152 not eaten, and any food eaten that was not prescribed, to be analyzed for compliance.
153 Participants will not be informed which diet is the intervention diet or the control diet.

154 Study participants will be randomly assigned to one of the two diets for four weeks, before
155 crossing over to the other diet, with a four-week washout period between diets.

156 *Average Protein Diet*: a control comparator diet that is similar to the ‘typical Australian
157 diet’ will be delivered at calculated energy balance based on equations we have previously

158 validated (19). This diet consists of 20% protein, 35% fat (<10% saturated), and 45%
159 carbohydrate, with >30 g of fiber daily. This group will receive the same information and study
160 visits as the other group.

161 *Reduced Protein Diet:* this is the intervention diet and will be similar to the *Average Protein*
162 *Diet*, except that macronutrients will be given at 10% protein, 35% fat (<10% saturated), and
163 55% carbohydrate, with >30 g of fiber daily. This diet will provide 0.7 g of protein per kg of
164 body weight (the recommended minimum daily protein intake).

165 The macronutrient profile of the diets will be manipulated with the assistance of a high or
166 low-protein supplemental powder to keep the diets as similar as possible to enable masking of
167 the diet groups. The supplemental powders are commercially available products. To retain
168 masking, they have been repackaged into silver foil pouches that are devoid of information.
169 The powders are dairy-based; because side effects linked to lactose intolerance could arise,
170 lactose intolerance is included as an exclusion criterion. Menus will be designed to allow
171 options for the method of consumption of the powder, but generally the powder will be
172 consumed mixed with a liquid (e.g. milk or water) as a drink. Most of the food will be provided
173 but study participants will be asked to buy some perishable grocery items (eg. fresh milk, juice,
174 fruits, and vegetables).

175 To prevent study participants from trying to guess which diet is the ‘Average Protein Diet’
176 and which diet is the ‘Reduced Protein Diet’ and therefore avoid bias, the participant
177 information sheet does not outline that the purpose of the study is to investigate the effect of
178 dietary protein intake on autophagy. The wording has been kept general and states that the
179 study aims to measure the effect of diet composition on autophagy in humans.

180 *Study visits*

181 Participants will attend four visits in addition to the screening visits. Two visits will take
182 place at the beginning of each diet (V1 and V3), and two visits at the end of each diet (V2 and
183 V4). The study flow chart is illustrated in **Figure 1**.

184 Participants are asked to fast (including from alcohol and caffeine) and refrain from
185 strenuous exercise for 12 hours overnight prior to a study visit. Participants attend the study
186 visits at SAHMRI North Terrace Adelaide. Study visits are booked in the morning, usually
187 between 7:30 – 9:00 am, at the participants' convenience.

188 Eligible participants will attend a first visit (V1) where they will be randomly assigned to
189 one of the two study diets. They will be given diet instructions before starting the intervention.
190 During the first four weeks of the intervention phase, they will receive a 7-day repeating menu
191 plan and matching menu checklists. There will be a short mid diet check-in survey
192 automatically sent via REDCap to the participants at day 14 of each diet period to monitor
193 adherence to the diet and flag any issues participants may be experiencing. After four weeks
194 following the first study diet, study participants will attend a second visit (V2). A four-week
195 washout period begins following V2 and participants will be advised to consume their regular
196 diet. At the end of the washout period, participants will attend a third visit (V3) and be allocated
197 to the diet that they were not allocated to during the first four weeks. They will be given the
198 same instructions as during V1. After four weeks following the second diet, they will attend
199 SAHMRI for a last visit (V4).

200 An additional SPIRIT (Standard Protocol Items: Recommendations for Interventional
201 Trials) checklist and an additional figure have been provided for further details regarding the
202 study of enrolment, interventions, and assessments for the current study (**Additional file 2** and
203 **Figure 2**).

204 *Data and biochemical samples collected*

205 *Anthropometry and blood pressure*

206 Height will be measured without shoes to the nearest 0.1 cm using a wall mounted
207 stadiometer. Weight will be measured after voiding, with clothing to the nearest 0.1 kg using a
208 calibrated scale (InBody230, InBody Co). Waist circumference will be measured at the mid-
209 axillary line (halfway point between the lowest rib and the top of the iliac crest), and hip
210 circumference will be measured at the widest circumference of the buttocks using a metal
211 measuring tape. Body mass index (BMI) will be calculated as weight in kilograms divided by
212 height in meters squared. Body composition will be assessed by Bioelectrical Impedance
213 Analysis (BIA) (InBody230, InBody Co). Blood pressure will be measured using an automatic
214 digital monitor and appropriately sized cuff after the participant has been seated for 10 minutes
215 at rest.

216 Hand grip strength

217 Hand grip strength will be assessed by a digital hand dynamometer (Jamar Plus, Serial
218 number 96179, Performance Health, S.I. Instruments Pty Ltd).

219 Blood collection

220 Fasting blood samples (up to 60 mL) will be collected by venipuncture and processed
221 immediately or within 30 minutes.

222 Autophagic flux measurement

223 Autophagic flux will be measured according to the method developed by Bensalem et al
224 (14). Briefly, 6 mL of each blood sample is split into two tubes: one tube will be treated with
225 chloroquine (CQ) to block lysosomal degradation of autophagic cargo LC3-II and the other
226 will be left untreated (unblocked); each sample will then be incubated for 1 h at 37°C. PBMCs
227 are then isolated from both tubes and stored frozen at -80°C for subsequent analysis of protein
228 LC3-II cargo accumulation by ELISA using a commercially available kit. Autophagic flux is
229 determined by the difference in the accumulation of LC3-II over time between blocked and

230 unblocked samples (i.e., what should have been degraded during the one-hour incubation)
231 using the equation $\Delta\text{LC3-II} = (\text{LC3-II}_{+\text{CQ}} - \text{LC3-II}_{-\text{CQ}})/\text{hour}$.

232 Autophagy-related markers

233 Change in autophagy-related proteins and mRNA will be assessed by western blot and/or
234 RT-qPCR (e.g., phospho-mTOR, phospho-S6 ribosomal protein, phospho-5' adenosine
235 monophosphate-activated protein kinase [AMPK], sequestosome-1 [P62/SQSTM1],
236 lysosomal-associated membrane protein 1 [LAMP1]). Molecular cell damage (e.g., lipid
237 oxidation, oxidative stress) will be analyzed using commercially available assays. Analysis of
238 nucleic acids will not reveal sequence-level data and will be used to measure transcript
239 abundance (gene expression) only. Genetic data will not be generated or revealed during this
240 study.

241 Biological material (e.g. plasma, leukocytes) isolated and stored during this project may be
242 used to identify autophagy biomarkers via, but not limited to, proteomic, metabolomic and/or
243 lipidomic analyses. Material may also be used to develop techniques that allow the
244 measurement of autophagy-related markers in a way that permits identification of specific cell
245 types (such as with flow cytometry) or test reagents or proteins (modified or unmodified) that
246 may be added to blood or cells for the measurement of autophagy and lysosomal processes.

247 Plasma hormones, amino acids, and lipids

248 Plasma will be snap frozen at -80°C for later assessment of blood glucose, insulin, blood
249 lipids, free fatty acids, glucose regulating hormones (e.g., insulin, C-peptide, adiponectin),
250 inflammatory cytokines (e.g., C-reactive protein), and appetite-regulating hormones (e.g.,
251 glucagon-like peptide-1 [GLP-1], glucose-dependent insulinotropic polypeptide [GIP],
252 ghrelin) using commercially available kits. Plasma amino acids will be analyzed by mass
253 spectrometry. Lipids (e.g., total cholesterol, high-density lipoprotein, low-density lipoprotein,
254 triglycerides) will also be analyzed.

255 Questionnaires

256 To investigate whether dietary protein intake impacts mental status, sleep quality, eating
257 habits, quality of life, and changes in physical activity, a series of questionnaires will be
258 administered before and during the study period: the Short Form 36 (SF-36) (20) to assess the
259 quality of life; the Pittsburgh Sleep Quality Index (PSQI) (21) to assess self-rated sleep habits
260 during the last month; the Three Factor Eating Questionnaire (TFEQ) (22) to assess three
261 cognitive and behavioral domains (or 'factors') of eating - cognitive restraint, disinhibition, and
262 hunger; and the Physical Activity Questionnaire IPAQ (23).

263 In addition to the questionnaires, a survey will be conducted at the completion of each study
264 diet (V2 and V4) and at the end of the overall study. This will collect qualitative data about
265 study expectations, perceptions, and experiences.

266 Sample size calculation

267 With existing data available to estimate the expected change in Δ LC3-II (i.e. autophagic
268 flux) between diets, we have assumed a change within-subject of 15%. Based on previously
269 observed Δ LC3-II mean of 277.862 ng LC3B-II/mg protein/h and an SD of 90.675 in healthy
270 subjects, assuming a change of 15% within-subject between both diets, $\alpha = 0.05$ and a power
271 of 80%, requires a sample size of 53 participants based on a paired Student's t-test (two-tailed).
272 Assuming a 15% dropout rate, we will recruit $n = 61$ participants.

273 Planned outcomes

274 Primary outcome measure

- 275 • Δ Autophagic flux

276 Secondary outcome measures

- 277 • Δ Autophagy-related markers
278 • Δ Body weight
279 • Δ Body composition

- 280 • Δ Blood metabolic markers [lipids, glucose, insulin, amino acids]
- 281 • Δ Blood pressure
- 282 • Δ Muscular strength
- 283 • Δ Quality of life
- 284 • Δ Self-rated sleep habits
- 285 • Δ Eating behaviours
- 286 • Δ Physical activity
- 287 • Diet satisfaction and preference

288 *Statistical plan*

289 Outcomes will be analyzed using linear mixed effects models to estimate the effect of diet,
290 expressed as a difference in means with 95% confidence interval and 2-sided p-value. Models
291 will account for potential period effects and baseline measurement. Demographic
292 characteristics will be summarized using descriptive statistics.

293 *Data management*

294 Upon screening, participants are assigned a unique study-specific identifier that is used on
295 all data collection documentation after confirming their enrolment in the study. All electronic
296 data collection and documentation is stored on a password protected REDCap database on
297 SAHMRI's secure server and can only be accessed by designated research team members. Any
298 paper copies of data will be stored in a locked cabinet within a security swipe card accessed
299 area in SAHMRI.

300 Biospecimens are stored at SAHMRI in secured freezers, all of which are monitored by a
301 central alert system 24 hours per day seven days a week.

302 No Data Monitoring Committee (DMC) will be required as this study does not involve
303 significant safety concerns, risks, or complexity.

304 The results of the study will be made publicly available via official publication and media
305 release at the study's conclusion.

306

307 **Discussion**

308 This study will indicate whether reducing protein intake could be developed as a nutritional
309 strategy to change autophagy to promote health and prevent autophagy-related diseases such
310 as Alzheimer disease or atherosclerosis.

311

312 **Trial status**

313 This study was registered on the 10th of March 2023 at anzctr.gov.au under identifier
314 ACTRN12623000260628. The first participant was randomized into the study on the 11th of
315 May, 2023. At the time of submission, randomization of participants into the study was still
316 open. If any important changes to the study protocol become necessary, where appropriate, the
317 PI will notify the HREC, trial register, and the present journal. At time of submission, the
318 current protocol number was version 5.2 dated 30th May 2024. The study is subject to audit at
319 any time by the HREC.

320

321 **List of abbreviations**

322 **AMPK:** 5' adenosine monophosphate-activated protein kinase

323 **ANZCTR:** Australian New Zealand Clinical Trials Registry

324 **BMI:** Body mass index

325 **CQ:** Chloroquine

326 **CRP:** C-reactive protein

327 **ELISA:** Enzyme-linked immunosorbent assay

328 **GIP:** Glucose-dependent insulintropic polypeptide

- 329 **GLP-1:** Glucagon-like peptide-1
- 330 **HREC:** Human Research Ethics Committee
- 331 **LAMP1:** Lysosomal-associated membrane protein 1
- 332 **LC3-II:** Microtubule-associated proteins 1A/1B light chain 3B II
- 333 **mTORC1:** Mechanistic target of rapamycin complex 1
- 334 **P62/SQSTM1:** Sequestosome-1
- 335 **PBMCs:** Peripheral blood mononuclear cells
- 336 **REDCap:** Research Electronic Data Capture
- 337 **SAHMRI:** South Australian Health and Medical Research Institute
- 338 **SD:** Standard deviation
- 339 **SPIRIT:** Standard Protocol Items: Recommendations for Interventional Trials

340

341 **Declarations**

342 *Ethics approval and consent to participate*

343 The study was approved by the University of Adelaide HREC on 30th of August 2021
344 (HREC reference number: H-2021-154). Study participants have all study details explained to
345 them in writing and in person before giving informed consent.

346 The present study is conducted in full cooperation with the World Health Organization's
347 International Standards for Clinical Trial Registries.

348 *Consent for publication*

349 Not applicable.

350 *Availability of data and materials*

351 Not applicable.

352 *Competing interests*

353 TJS and JB are listed as inventors on a related patent—Australia (Provisional) 2019903187;

354 2019904822; PCT/AU/2020/050908; United Kingdom GB2603664B; USA 17/637,494.

355 *Funding*

356 This work is supported by *Lysosomal Health in Ageing* at SAHMRI and the BrightFocus
357 Foundation, USA (A2021040S). The funders have no role in study design, data collection and
358 analysis, and in the decision to publish or the preparation of the manuscript.

359 *Authors' contributions*

360 CF assisted with the study conception, wrote the first draft of the ethics protocol, and wrote
361 the first draft of the manuscript. LKH conceived the study, assisted with writing the ethics
362 protocol, and obtained funding for the study. XTT assisted with study conception and designed
363 the dietary interventions. JRG assisted with writing the ethics protocol and registered the study.
364 TS conceived the study, assisted with writing the ethics protocol, registered the study, and
365 obtained funding for the study. JB conceived the study, wrote the first draft of the ethics
366 protocol, obtained funding for the study, and wrote the first draft of the manuscript. All authors
367 critically revised the manuscript and approved the final manuscript.

368 *Acknowledgment*

369 Acknowledgment is made to the donors of the Standard Award Program in Alzheimer's
370 Disease Research grant (A2021040S), a program of the BrightFocus Foundation, for support
371 of this research. We acknowledge the University of Adelaide HREC for reviewing our ethics
372 application.

373

374 **References**

375 1. Carosi JM, Fourrier C, Bensalem J, Sargeant TJ. The mTOR-lysosome axis at the centre
376 of ageing. *FEBS Open Bio*. 2022 Apr;12(4):739-757.

- 377 2. Hein LK, Apaja PM, Hattersley K, Grose RH, Xie J, Proud CG, Sargeant TJ. A novel
378 fluorescent probe reveals starvation controls the commitment of amyloid precursor protein to
379 the lysosome. *Biochim Biophys Acta Mol Cell Res.* 2017;1864(10):1554-65.
- 380 3. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of
381 autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent
382 autophagosome marker. *Mol Biol Cell.* 2004;15(3):1101-11.
- 383 4. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through
384 direct phosphorylation of Ulk1. *Nat Cell Biol.* 2011;13(2):132-41.
- 385 5. Wahl D, Solon-Biet SM, Wang QP, Wali JA, Pulpitel T, Clark X, et al. Comparing the
386 Effects of Low-Protein and High-Carbohydrate Diets and Caloric Restriction on Brain Aging
387 in Mice. *Cell Rep.* 2018;25(8):2234-43 e6.
- 388 6. Bensalem J, Hein LK, Hassiotis S, Trim PJ, Proud CG, Heilbronn LK, Sargeant TJ.
389 Modifying Dietary Protein Impacts mTOR Signaling and Brain Deposition of Amyloid β in a
390 Knock-In Mouse Model of Alzheimer Disease. *J Nutr.* 2023;153(5):1407-19.
- 391 7. Solon-Biet SM, McMahon AC, Ballard JW, Ruohonen K, Wu LE, Cogger VC, et al.
392 The ratio of macronutrients, not caloric intake, dictates cardiometabolic health, aging, and
393 longevity in ad libitum-fed mice. *Cell Metab.* 2014;19(3):418-30.
- 394 8. Levine ME, Suarez JA, Brandhorst S, Balasubramanian P, Cheng CW, Madia F, et al.
395 Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality
396 in the 65 and younger but not older population. *Cell Metab.* 2014;19(3):407-17.
- 397 9. Zhang X, Kapoor D, Jeong SJ, Fappi A, Stitham J, Shabrish V, et al. Identification of
398 a leucine-mediated threshold effect governing macrophage mTOR signalling and
399 cardiovascular risk. *Nat Metab.* 2024;6(2):359-77.

- 400 10. Zhang X, Sergin I, Evans TD, Jeong SJ, Rodriguez-Velez A, Kapoor D, et al. High-
401 protein diets increase cardiovascular risk by activating macrophage mTOR to suppress
402 mitophagy. *Nat Metab.* 2020;2(1):110-25.
- 403 11. Bensalem J, Fourrier C, Hein LK, Hassiotis S, Proud CG, Sargeant TJ. Inhibiting
404 mTOR activity using AZD2014 increases autophagy in the mouse cerebral cortex.
405 *Neuropharmacology.* 2021;190:108541.
- 406 12. Fourrier C, Bryksin V, Hattersley K, Hein LK, Bensalem J, Sargeant TJ. Comparison
407 of chloroquine-like molecules for lysosomal inhibition and measurement of autophagic flux in
408 the brain. *Biochem Biophys Res Commun.* 2021;534:107-13.
- 409 13. Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E. Lysosomal turnover, but not a
410 cellular level, of endogenous LC3 is a marker for autophagy. *Autophagy.* 2005;1(2):84-91.
- 411 14. Bensalem J, Hattersley KJ, Hein LK, Teong XT, Carosi JM, Hassiotis S, et al.
412 Measurement of autophagic flux in humans: an optimized method for blood samples.
413 *Autophagy.* 2021;17(10):3238-55.
- 414 15. McKee TJ, Komarova SV. Is it time to reinvent basic cell culture medium? *Am J*
415 *Physiol Cell Physiol.* 2017;312(5):C624-C6.
- 416 16. Sargeant TJ, Bensalem J. Human autophagy measurement: an underappreciated barrier
417 to translation. *Trends Mol Med.* 2021;27(12):1091-4.
- 418 17. Shang X, Scott D, Hodge AM, English DR, Giles GG, Ebeling PR, Sanders KM.
419 Dietary protein intake and risk of type 2 diabetes: results from the Melbourne Collaborative
420 Cohort Study and a meta-analysis of prospective studies. *Am J Clin Nutr.* 2016;104(5):1352-
421 65.
- 422 18. Gluck ME, Geliebter A, Satov T. Night eating syndrome is associated with depression,
423 low self-esteem, reduced daytime hunger, and less weight loss in obese outpatients. *Obes Res.*
424 2001;9(4):264-7.

425 19. Heilbronn LK, de Jonge L, Frisard MI, DeLany JP, Larson-Meyer DE, Rood J, et al.
426 Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and
427 oxidative stress in overweight individuals: a randomized controlled trial. *JAMA*.
428 2006;295(13):1539-48.

429 20. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
430 Conceptual framework and item selection. *Med Care*. 1992;30(6):473-83.

431 21. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep
432 Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res*.
433 1989;28(2):193-213.

434 22. Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary
435 restraint, disinhibition and hunger. *J Psychosom Res*. 1985;29(1):71-83.

436 23. Hagstromer M, Oja P, Sjostrom M. The International Physical Activity Questionnaire
437 (IPAQ): a study of concurrent and construct validity. *Public Health Nutr*. 2006;9(6):755-62.

438

439 **Figures and Additional files**

440 **Figure 1. Experimental design of the NINA study.** Diet A or Diet B represent the Average
441 Protein Diet and the Reduced Protein Diet, respectively. The randomization will determine the
442 order A-B or B-A.

443

444 **Figure 2. SPIRIT figure. Schedule of enrolment, interventions, and assessments.**

445

446 **Additional file 1. Study information sheet.** Detailed study information is provided to
447 participants during screening, before the first study visit, and before written consent is obtained.
448 The study information sheet is followed by the participant consent form.

449

450 **Additional file 2. SPIRIT checklist.** SPIRIT checklist listing all the items addressed in the

451 current study protocol.

452

FIGURE 1




FIGURE 2

TIMEPOINT*	Screening		STUDY PERIOD							
	-t ₂	-t ₁	Post-enrolment							
			t ₁	t ₂	t ₃	t ₄	t ₅	t ₆	t ₇	
ENROLMENT:										
Eligibility screen (online, REDCap)	X									
Screening phone call	X									
Screening appointment (informed consent)		X								
Randomization			X							
INTERVENTIONS:										
First 4-week intervention			←————→							
Washout period (4 weeks)						X				
Second 4-week intervention							←————→			
ASSESSMENTS:										
Anthropometric measurements		X	X		X		X		X	
Blood pressure		X	X		X		X		X	
Night Eating Diagnostic Questionnaire	X									
Body composition (BIA)			X		X		X		X	
Hand grip strength			X		X		X		X	
The Short Form 36 (SF-36) questionnaire			X		X		X		X	
Pittsburgh Sleep Quality Index (PSQI)			X		X		X		X	
Three Factor Eating Questionnaire (TFEQ)			X		X		X		X	
Physical Activity Questionnaire IPAQ			X		X		X		X	
Blood collection			X		X		X		X	
Autophagic flux measurement			X		X		X		X	
Autophagy-related markers			X		X		X		X	
Plasma hormones, amino acids, and lipids			X		X		X		X	
End of diet survey					X				X	
End of study survey									X	
REDCap mid-diet survey and possible follow-up				X				X		

***Timepoints:**

- t₂ = pre-screening online via REDCap
- t₁ = screening at clinic and enrolment
- t₁ = baseline visit for first diet, V1
- t₂ = mid-diet survey check-in
- t₃ = end of first diet, V2
- t₄ = washout period
- t₅ = baseline visit for second diet, V3
- t₆ = mid-diet survey check-in
- t₇ = end of second diet, V4